International journal of rheumatic diseases · 2026
Metformin Suppress Th17 Differentiation and Function to Improve Glandular Function in Primary Sjögren's Syndrome.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Jian, Liu Mengli, Fan Zhou, Li Zhuoyue, Wang Longfei, Wang Lili, Mei Yongjun, Liu Zhirong
Аннотация
PURPOSE: This study aims to investigate the effects of metformin on T cell differentiation and the underlying mechanisms in NOD/Ltj mice, a model for primary Sjögren's syndrome (pSS). Specifically, we focus on metformin's role in modulating Th17 differentiation and its potential regulation through the mTOR/STAT3 signaling pathway.
METHODS: We established a metformin-treated pSS mouse model. Salivary flow rate, histological analysis, and flow cytometry were employed to assess inflammation and T cell subsets. Cytokine secretion was measured using qPCR, ELISA, and Western blot analysis. To investigate the molecular pathways involved, we examined mTOR/STAT3 signaling and administered mTOR and STAT3 agonists.
RESULTS: Metformin treatment significantly alleviated salivary gland inflammation and increased salivary flow in pSS mice. Flow cytometry showed that metformin reduced the proportions of Th1, Th2, and Th17 cells, while increasing Treg cells. The reduction in Th17 cells was the most prominent. Furthermore, metformin decreased the levels of pro-inflammatory cytokines (IL-21, IL-22, IFN-γ) and increased anti-inflammatory cytokines (IL-4, IL-10). Immunohistochemistry and Western blot analysis demonstrated that metformin inhibited IL-17 expression. Additionally, metformin treatment suppressed the mTOR/STAT3 signaling pathway, and mTOR/STAT3 agonists reversed the effects of metformin on Th17 differentiation.
CONCLUSION: Metformin effectively modulates T cell differentiation and alleviates pSS symptoms, primarily by suppressing Th17 cell differentiation through the mTOR/STAT3 pathway. These findings provide insights into the therapeutic mechanisms of metformin in pSS and suggest its potential as a treatment strategy for immune-mediated diseases.
METHODS: We established a metformin-treated pSS mouse model. Salivary flow rate, histological analysis, and flow cytometry were employed to assess inflammation and T cell subsets. Cytokine secretion was measured using qPCR, ELISA, and Western blot analysis. To investigate the molecular pathways involved, we examined mTOR/STAT3 signaling and administered mTOR and STAT3 agonists.
RESULTS: Metformin treatment significantly alleviated salivary gland inflammation and increased salivary flow in pSS mice. Flow cytometry showed that metformin reduced the proportions of Th1, Th2, and Th17 cells, while increasing Treg cells. The reduction in Th17 cells was the most prominent. Furthermore, metformin decreased the levels of pro-inflammatory cytokines (IL-21, IL-22, IFN-γ) and increased anti-inflammatory cytokines (IL-4, IL-10). Immunohistochemistry and Western blot analysis demonstrated that metformin inhibited IL-17 expression. Additionally, metformin treatment suppressed the mTOR/STAT3 signaling pathway, and mTOR/STAT3 agonists reversed the effects of metformin on Th17 differentiation.
CONCLUSION: Metformin effectively modulates T cell differentiation and alleviates pSS symptoms, primarily by suppressing Th17 cell differentiation through the mTOR/STAT3 pathway. These findings provide insights into the therapeutic mechanisms of metformin in pSS and suggest its potential as a treatment strategy for immune-mediated diseases.